[DISCLOSURE]
Kolon Life Science (102940) announced on Nov. 19 that it has signed a US$591.60 million contract with Mundipharma Medical Company licensing technologies of Invossa-K in Japan.
This amounts to 565 percent of its 2017 revenue and the contract is valid for 15 years from launching the therapy in Japan.
By Hwang You-mee (
glamazon@heraldcorp.com)